Epstein-Barr virus infections after allogeneic stem cell transplantation: A comparison between non-malignant and malignant hematological disorders

Hematology

Volumn 15, Issue 5, 2010, Pages 344-350

  Islam, Md Serajul ^a   Anoop, Parameswaran ^a   Gordon Smith, Edward C ^a   Rice, Phil ^a   Datta Nemdharry, Preeti ^a   Marsh, Judith C W ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

EBV; malignant; non malignant; risk; transplantation

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; METHOTREXATE; RITUXIMAB; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION COMPLICATION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTILYMPHOCYTE SERUM; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77957300650     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12647083621047     Document Type: Article

References (26)

1. Cohen JM, Cooper N, Chakrabarti S et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007;48(2):256-269.
2. Rickinson AB, Lee SP, Steven NM. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996;8(4):492-497.
3. van Esser JW, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98(4):972-978.
4. + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003;101(11):4290-4297.
5. Chakrabarti S, Milligan DW, Pillay D et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102(3):839-842.
6. Juvonen E, Aalto S, Tarkkanen J et al. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. Haematologica 2007;92(6):819-825.
7. Brunstein CG, Weisdorf DJ, DeFor T et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006;108(8):2874-2880.
8. Juvonen E, Aalto SM, Tarkkanen J et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003;32(1):97-102.
9. Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following Allo-SCT for acquired aplastic anemia. Bone Marrow Transplant 2009;43(10):813-816.
10. Marsh JC, Ball SE, Cavenagh J et al. British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2009;147(1):43-70.
11. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15(6):825-828.
12. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9(4):215-233.
13. Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007;83(11):1423-1428.
14. Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68(10):1517-1525.
15. Stevens SJ, Verkuijlen SA, Brule AJ, Middeldorp JM. Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA loads in clinical specimens. J Clin Microbiol 2002;40(11):3986-3992.
16. Falcao RP, Voltarelli JC, Bottura C. Some immunological studies in aplastic anemia. J Clin Lab Immunol 1983;10(1):25-28.
17. Falcao RP, Voltarelli JC, Bottura C. T-cell subsets in patients with aplastic anemia. Braz J Med Biol Res 1984;17(2):151-156.
18. Islam MS, Anoop P, Rice P et al. Early cytomegalovirus infections following allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders. Hematology, 2010;15(1):4-10.
19. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008;15(6):576-585.
20. Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B. Monitoring of Epstein-Barr virus load after haematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 2008;80(3):441-454.
21. Meijer E, Spijkers S, Moschatsis S et al. Active Epstein-Barr virus infection after allogeneic stem cell transplantation: re-infection or reactivation? Transpl Infect Dis 2005;7(1):4-10.
22. Scheinberg P, Fischer SH, Li L et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007;109(8):3219-3224.
23. Ocheni S, Kroeger N, Zabelina T et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008;42(3):181-186.
24. Gupta V, Ball SE, Yi QL et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004;10(12):867-876.
25. + cell dose on clinical and haematological outcome of allogeneic stem cell transplantation for acquired aplastic anaemia. Bone Marrow Transplant 2010;45(5):886-894.
26. Marshall NA, Howe JG, Formica R et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000;96(8):2814-2821.